Warby Parker (WRBY) Non-Current Deffered Revenue (2020 - 2021)
Warby Parker (WRBY) reported Non-Current Deffered Revenue of $36.5 million for Q4 2021, up 30.53% on a YoY basis from $28.0 million in Q4 2020, and up 17.97% quarter-over-quarter from $31.0 million in Q3 2021.
Warby Parker (WRBY) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Warby Parker has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $36.5 million in Q4 2021.
- For the quarter ending Q4 2021, Non-Current Deffered Revenue rose 30.53% year-over-year to $36.5 million; the trailing twelve-month figure through Dec 2021 stood at $36.5 million (up 30.53% YoY), and the FY2021 full-year result was $36.5 million, up 30.53% from the prior year.
- Non-Current Deffered Revenue for Q4 2021 stood at $36.5 million, up from $31.0 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $36.5 million in Q4 2021, with the low at $28.0 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | - |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | - |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | - |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 163.15 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 11.80 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | - |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 208.80 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | - |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | - |
| 10 | Warby Parker | 3.11 Bn | 2.82 Bn | 131.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 36.54 Mn |
| Sep 30, 2021 | 30.98 Mn |
| Dec 31, 2020 | 28.00 Mn |